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Introduction:
Solid tumors make up about 60% of all pediatric cancers (1) . The most common types of solid tumors in children include brain tumors, neuroblastoma, rhabdomyosarcoma, Wilms' tumor, and osteosarcoma. Although significant progress has been made during the last decades in the treatment and prognosis of pediatric malignancies, high mortality is still prevalent in patients with advanced, unresectable, or high-grade disease. (2) . Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma and the third most common extracranial solid tumor in children following neuroblastoma and Wilm's tumor, with an annual incidence of 4-7 cases per million children under the age of 16 years (3, 4). Multimodal treatment has significantly improved survival to approximately 70%. Although a majority of patients achieve a complete remission with primary therapy, a substantial number still experience recurrences with poor prognosis (5) . In addition, at least 15% children with rhabdomyosarcoma present with metastatic disease (IRSG IV), and their prognosis has not improved significantly in the last 15 years (6).
Neuroblastoma (NB) is the most common extra-cranial childhood malignancy. It accounts for 8-10% of all pediatric malignancy, and is responsible for 15% of all childhood cancer deaths (7) .
Despite intensive treatment protocols including megatherapy with hematopoietic stem cell transplantation, the prognosis of patients with this malignancy remains poor. Disease-free survival is only about 30% for metastatic disease compared to 95% for localized tumors over 1 year (8, 9) .
Paclitaxel, originally isolated from Taxus brevifolia (Pacific Yew), is a cytotoxic microtubule stabilizing agent that stabilizes microtubules and as a result, interferes with the normal breakdown of microtubules during cell division, and lead to mitotic arrest (10) . This mitotic arrest triggers the mitotic spindle checkpoint and results in apoptosis (10) . Paclitaxel has also Author Manuscript Published OnlineFirst on August 29, 2013 ; DOI: 10.1158/1078-0432.CCR- been shown to mediate apoptosis through pathways that may be independent of gross microtubule dysfunction (11) (12) (13) . Paclitaxel is widely used in the treatment of various malignancies, including ovarian cancer, breast cancer, non-small cell lung carcinoma, bladder cancer, head and neck cancer, and a wide range of other malignancies (10, 14) . However, due to its very low aqueous solubility, conventional paclitaxel like Taxol uses a Cremophor EL/ethanol vehicle as the solvent. The Cremophor EL-containing paclitaxel formulation can cause severe allergic, hypersensitivity, and anaphylactic reactions in animals and humans which limited its application in pediatric cancer patients (15) (16) (17) . Although paclitaxel were reactive to several neuroblastoma cell lines in vitro, it displayed little efficacy in vivo in nude mice (18) . In a phase I trial in children with refractory solid tumors, severe acute neurological and allergic toxicity was encountered with 3-hour paclitaxel infusion after premedication (dexamethasone, dexchlorpheniramine) with one treatment-related death occurred (19) . For reasons that are still unclear, taxanes demonstrated minimal activity in treating solid tumors in children in several clinical trials (20) (21) (22) . Nab-paclitaxel (also known as ABI-007, Abraxane ® , Celgene Corporation, Summit, New Jersey) is a novel, solvent free, 130 nm, protein-stabilized formulation of paclitaxel that was developed to reduce the toxicity of solvent-based paclitaxel (known as Taxol) (23, 24) . In human adult tumor models, Nab-paclitaxel is effective in inducing regression of implanted human malignant carcinomas and prolonging survival in tumor-bearing mice (25) . Clinically, nab-paclitaxel is approved globally for the treatment of metastatic breast cancer (MBC) and is also recently approved in the United States (US) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. Since limited pediatric data are currently available, in this study, we tested the anti-tumor activity of nab-paclitaxel against different pediatric solid tumor models to support the development of early phase clinical trials in pediatric patients.
Materials and Methods

Materials and Reagents
Nab-paclitaxel (Celgene Corporation) was supplied as a lyophilized powder and stored at room temperature until reconstitution. Nab-paclitaxel was reconstituted following the package insert with 20 ml 0.9% saline to 5 mg/ml stock solution. The dosing solutions were prepared by diluting the stock solution with 0.9% saline to the desired concentration. Paclitaxel was dissolved in DMSO (Sigma Aldrich, Saint Louis) to 25 mg/ml stock solution. The dosing solutions were prepared by diluting the stock solution with 0.9% saline to the desired concentration.
The Annexin V-FITC Early Apoptosis Detection Kit was purchased from Cell Signaling 
Test Animals
Female NOD/SCID mice 4-6 weeks old were obtained from Charles River. Animals were housed in the animal facility of the Hospital for Sick Children, Toronto, Ontario, Canada. These studies were performed under a Hospital for Sick Children Animal Care Committee approval. 
Cell Viability Assay
Xenograft Development
The anti-tumor activity of nab-paclitaxel/paclitaxel was investigated in vivo against subcutaneous rhabdomyosarcoma (RH4 and RH30) and neuroblastoma (SK-N-BE (2) In tumor rechallenge experiments, when RH4 relapsed tumors from paclitaxel treatment reached 0.5 cm in diameter, we randomized these animals into two treatment groups (n=3): Nab-paclitaxel and paclitaxel. For nab-paclitaxel relapsed tumors, we randomized animals into two groups (n=3):
nab-paclitaxel treatment and saline control. Drugs were given with the same schedule and dosage as above. Tumor growth and animal body weight were monitored.
The anti-metastatic activity of nab-paclitaxel was further investigated in SK-N-BE (2) neuroblastoma metastatic models. Tumor cells were injected intravenously into the lateral tail vein (26-gauge needle, 1 x 10 6 cells in 100 μl total volume). Mice were randomized into 2 groups (control and nab-paclitaxel 50 mg/kg iv weekly) with 10 mice in each group and treatments started 14 days after inoculation until the event of endpoint. The event of endpoint was defined according to our animal committee guidelines as mice in severe clinical condition, such as loss of 20% of body weight, body temperature lower than 32°C, or signs of stress. The survival time of control and nab-paclitaxel treatment groups was compared and statistically analyzed.
Immunohistochemistry Staining
In order to assess the effect of nab-paclitaxel on inducing cell cycle arrest and apoptosis in vivo, SK-N-BE(2) subcutaneous xenografts treated with nab-paclitaxel or DMSO-paclitaxel were harvested at the end of study and analyzed by immunohistochemistry (IHC) for the apoptotic marker (cleaved caspase-3) and mitotic marker (phospho-histone H3). RH4 xenografts were harvested and analyzed by IHC for phospho-histone H3. Briefly, Formalin-fixed, paraffinembedded tissues were cut into 5um thick sections and immunostained with the polyclonal antibodies against cleaved caspase-3 (1:50; Cell Signaling, #9661) and histone H3 phospho S10 Anti-Rabbit Ig Peroxidase Reagent Kit (Vector Laboratories, #MP-7401) was used for detection followed by DAB and hematoxylin staining.
LC/MS Plasma/ Intratumor Concentration
Plasma and intratumor drug concentration was studied after single or repeated drug administration. In RH4 xenograft model, blood/tumor samples were collected 24 hours after the first dosage of nab-paclitaxel (50mg/kg) or paclitaxel (30mg/kg). In the SK-N-BE(2) xenograft model, paclitaxel (20mg/kg) and nab-paclitaxel (50mg/kg) were administered on day 1, 8 and 15.
Low-dose metronomic nab-paclitaxel (10mg/kg) was administered daily from day 1 to day 15. 
Statistical Analysis
Data from different experiments were presented as mean ± SD. For statistical analysis, Student's t test for independent means was used. A P value of < 0.05 was considered significant. To compare the effects of different treatments on tumor growth in vivo, one-way ANOVA with Dunnett multiple comparison test was used. Mann-Whitney U test was used in tumor rechallenge experiments for the statistical evaluation of significant differences in growth patterns between two study groups. Survival curve comparisons were performed using Graphpad Prism software for Kaplan-Meier Survival Analysis. than to paclitaxel dissolved in the solvent DMSO ( Figure 1D ), suggesting that paclitaxel in albumin-bound formulation in solution more readily available for tumor cell uptake.
Results
In vitro cytotoxicity of nab-paclitaxel against pediatric tumor cell lines
Nab-paclitaxel-induced apoptosis in Rhabdomyosarcoma cells
We further assessed cell apoptosis after in vitro drug treatment. Rhabdomyosarcoma RH4 cells 
In vivo anti-tumor activity of nab-paclitaxel against rhabdomyosarcoma
The in vivo anti-tumor activity of nab-paclitaxel was evaluated in multiple pediatric tumor xenografts. In rhabdomyosarcoma models, mice bearing RH4 and RD xenografts were treated intravenously with nab-paclitaxel (50mg/kg) and paclitaxel (30mg/kg). The 50 mg/kg weekly dose of nab-paclitaxel is estimated to be comparable to human maximum tolerated dose (MTD) 
the first week after paclitaxel administration, all mice showed signs of inappetence, hunched posture, dry feces, and significant body weight loss. Necropsy of the dead animal showed that both cecum and colon were distended with hard stools. Our results demonstrated that paclitaxel, even at a lower dose, had higher toxicity compared with nab-paclitaxel. In the RH4 model, increased local relapse-free intervals were observed with nab-paclitaxel treatment (37.7±3.2 days) comparing to paclitaxel (13.6±2.07 days).
In RD xenograft model, both paclitaxel and nab-paclitaxel treatment significantly inhibited tumor growth, but tumor shrinkage was only observed in nab-paclitaxel treated tumors (Fig. 2C) .
Efficacy of nab-paclitaxel in paclitaxel-resistant or relapsed rhabdomyosarcoma xenografts
In RH4 xenografts, either paclitaxel or nab-paclitaxel was administered on day 1, 8 and 15.
Complete regression was observed in paclitaxel treated mice after day 31 (Fig. 2D) . However, all paclitaxel treated animals demonstrated tumor relapse after 11-15 days. On day 52, when paclitaxel relapsed tumors reached 0.5 cm in diameter, we randomized animals into two treatment groups: nab-paclitaxel and paclitaxel. Drugs were given on day 52, 59 and 66 with the same schedule and dosage as above. As shown in Fig. 2D , relapse RH4 xenografts were drug resistant against paclitaxel, but remained sensitive to nab-paclitaxel treatment. Tumor regression was observed in all relapsed tumors which were treated again with nab-paclitaxel (P<0.05, Mann-Whitney U test).
Complete regression was observed in nab-paclitaxel treated mice after day 29 (Fig. 2E) . Six out of seven animals developed relapsed tumor after 37-42 days. On day 75, when nab-paclitaxel relapsed tumors reached 0.5 cm in diameter, we randomized animals into two groups: nabpaclitaxel treatment and saline control. Nab-paclitaxel or saline was given on day 75, 82 and 87 with the same schedule and dosage as above. As seen in Fig. 2E , when we treated those relapsed RH4 tumors with nab-paclitaxel (50mg/kg, weekly) again, refractory tumors remained responsive to nab-paclitaxel. We observed significant difference between nab-paclitaxel rechallenge and control tumor volumes (P<0.05, Mann-Whitney U test).
In RD xenograft model, paclitaxel (30mg/kg, weekly) or nab-paclitaxel (50mg/kg, weekly) was administered on day 1 and 8. Tumor regression was observed with nab-paclitaxel treatment.
Comparing to control animals, paclitaxel treatment was able to slow the growth of RD tumors, but those tumors grew progressively with no signs of tumor regression. On day 15, when we replaced the paclitaxel drug treatment with nab-paclitaxel (50mg/kg, weekly), those tumors regressed rapidly after the first dosage of nab-paclitaxel (Fig. 2C) 
Anti-tumor effects of nab-paclitaxel with different regimens in NB models
We further compared different schedules and doses of nab-paclitaxel, low-dose metronomic (LDM) and standard maximum tolerated dose (MTD) schedule in NB xenograft models. mg/kg i.v. weekly) with all treatments starting 14 days after tumor cell inoculation. As shown in Figure 3C , nab-paclitaxel treatment significantly prolonged animal survival compared with the control group (median survival of 59 days for nab-paclitaxel group vs. 32 days for control group; P<0.01). Nab-paclitaxel treatment significantly increased body weight in these mice (Fig. 3D) compared to control.
Plasma and tumor paclitaxel concentrations following nab-paclitaxel treatment
Plasma and intratumor drug concentration was measured after single or repeated drug administration (details in "Materials and Methods" section). Twenty-four hours after the last dose, blood and tumor samples were collected and analyzed for paclitaxel concentration by LC/MS. In both tumor models, nab-paclitaxel treatment displayed lower plasma paclitaxel concentrations compared to DMSO-paclitaxel, whereas the intratumor paclitaxel concentrations were higher with nab-paclitaxel groups ( Figure 4A, 4B) . As a consequence, nab-paclitaxel had a higher tumor/plasma paclitaxel ratio compared to DMSO-paclitaxel 24 hours after drug administration.
Nab-paclitaxel induced cell apoptosis and cell cycle arrest
To determine whether the anti-tumor activity of nab-paclitaxel was the result of tumor cells apoptosis and cell cycle arrest, SK-N-BE(2) xenografts treated with different dosages of nabpaclitaxel were harvested at the end of study and analyzed by immunohistochemistry (IHC) for the apoptotic marker (cleaved caspase-3) and mitotic marker (phospho-histone H3). Furthermore, a recent phase III trial in patients with metastatic breast cancer compared nabpaclitaxel with paclitaxel. Nab-paclitaxel resulted in significantly higher response rates and time to tumor progression than paclitaxel. There was no incidence of grade 3/4 hypersensitivity reactions in the group of patients treated with nab-paclitaxel, despite the absence of premedication. Toxicity data showed that nab-paclitaxel resulted in less grade 4 neutropenia than paclitaxel, and although the incidence of grade 3 sensory neuropathy was higher with nabpaclitaxel, the time until the neuropathy decreased to grade 2 was significantly less with nabpaclitaxel compared with paclitaxel (29).
Our results have shown that nab-paclitaxel is effective against both rhabdomyosarcoma and neuroblastoma in preclinical models. We also shown that nab-paclitaxel is more active than paclitaxel in all tumor models tested. With this new formulation, we were able to administer 50mg/kg of nab-paclitaxel to testing animals, a much higher dosage compared to paclitaxel (30mg/kg). No mortality and significant body weight loss were observed in nab-paclitaxel treated animals. Toxicity studies performed by Abraxis BioScience compared the effects of single and repeated doses of nab-paclitaxel and Taxol in a number of animal species. In all cases, the MTD of nab-paclitaxel was higher than for Taxol [26] . These data suggested that nabpaclitaxel were less toxic than Taxol, and our results showed that nab-paclitaxel was better tolerated than DMSO-paclitaxel.
We also demonstrated that, in tumor-bearing mice in vivo, increased intratumor and correspondingly lower plasma paclitaxel levels were observed with nab-paclitaxel compared to DMSO-paclitaxel, resulting in higher tumor/plasma paclitaxel drug ratio for nab-paclitaxel. A higher intratumoral concentration produces a greater cytotoxic effect since tumor cell death is proportional to drug concentration. The lower plasma drug concentration may limit total body 
exposure to the cytotoxic agent resulting in reduced systemic toxicity. Nab-paclitaxel, the 130-nm nanoparticle formulation albumin-bound paclitaxel, utilizes the natural properties of albumin to reversibly bind paclitaxel, transport it across the endothelial cell and concentrate in tumors.
The underlying mechanism is reported to involve an endothelial cell-surface albumin receptor (gp60) and an albumin-binding protein expressed by tumor cells and secreted into the tumor interstitium (secreted protein, acidic and rich in cysteine, SPARC). gp60 is believed to mediate transcytosis of the albumin nanoparticles through endothelial cells, and binding to SPARC purportedly leads to drug accumulation in tumor tissues and thereby enhances the therapeutic efficacy of nab-paclitaxel compared to the paclitaxel free drug (30, 31) . Additional retention of the nanoparticles in the tumor interstitium is believed to be due to the aberrant tumor angiogenesis and compromised clearance via lymphatics. This so-called ''enhanced permeability and retention effect'' results in an important intratumoral drug accumulation that is even higher than that observed in plasma and normal tissues (32, 33) . Clinically, nab-paclitaxel has been shown to enhance the binding of paclitaxel to albumin, microtubules, and cells and increase the tissue availability of paclitaxel when compared to solvent-based paclitaxel, since the albuminbound paclitaxel is not trapped in the plasma compartment by Cremophor EL micelles (23, 34, 35) . The results from the current study were consistent with previous data in that nab-paclitaxel had lower plasma concentration (faster tissue distribution) and higer tumor accumulation compared with a solvent-based paclitaxel (25) . Recent publication by Cossimo and colleagues demonstrated that some oncogene transformed cells appear to use macropinocytosis to transport extracellular protein into the cell (36) , which potentially contributes to the uptake of albumin- As with other chemotherapeutic drugs, resistance is commonly seen with paclitaxel treatment.
Different mechanisms of paclitaxel resistance haven been reported including overexpression of multidrug resistance (MDR-1) gene (37) , molecular alterations in the target molecule (β-tubulin) (38) , changes in apoptotic regulatory and mitosis checkpoint proteins (39) , and changes in lipid composition and potentially the overexpression of interleukin 6 (IL-6) (40) . Recent studies with array-based technology have demonstrated that paclitaxel resistance is associated with simultaneous changes in numerous genes (41, 42) . It is likely that multiple intracellular and extracellular pathways are involved in the paclitaxel resistant phenotype. Certain types of nanoparticles were found to be able to overcome multidrug resistance mediated by the Pglycoprotein efflux system localized at the cancerous cell membrane. The drug export transporter P-glycoprotein (P-gp) can remove a large range of drugs from the cell, and upregulation of P-gp makes it possible for cancer cells to become completely resistant to some of the drugs intensively used in the clinic, notably taxanes, anthracyclines, epipodophylotoxins and Vinca alkaloids (43). P-gp reversion by nanoparticles was explained by a local delivery of the drug in high concentration close to the cell membrane. Such high local microconcentration of cytotoxic drugs was able to saturate P-glycoprotein (44) . In this study, we observed that paclitaxel relapsed tumors developed resistance against paclitaxel treatment, while those tumors are responsive to nab-paclitaxel treatment. We believe that the superior efficacy of nab-paclitaxel vs. paclitaxel in the series of rechallenging experiments most possibly derived from the higher intratumor drug distribution and improved anti-tumor activity by nab-paclitaxel, as demonstrated in the in vitro cytotoxicity study (Figure 1 ) and xenograft study (Figure 2A 
